Format

Send to

Choose Destination
J Cancer Res Clin Oncol. 2019 Jun;145(6):1377-1385. doi: 10.1007/s00432-019-02879-2. Epub 2019 Apr 8.

The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer.

Author information

1
Department of Transfusion Medicine, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, People's Republic of China.
2
Department of Transfusion Medicine, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, People's Republic of China. friday0451@163.com.
3
Department of Transfusion Medicine, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, People's Republic of China. xiarongcn@126.com.

Abstract

PURPOSE:

During the past decades, PD-1/PD-L1 axis blockade has become a remarkable promising therapy which has exerted durable anti-tumor effect and long-term remissions on part of cancers. However, there are still some patients which do not show good response to the PD-1/PD-L1 targeted monotherapy. Till now, the widely accepted anti-tumor mechanism of PD-1/PD-L1 blockade is rejuvenating T cells, there is lack of studies which focus on other components of the tumor environment in the treatment of cancer with PD-1/PD-L1 blockade, especially the complicated relationship between macrophages and PD-1/PD-L1 pathway during the progression and treatment of cancer.

METHODS:

The relevant literatures from PubMed have been reviewed in this article.

RESULTS:

Even though the widely accepted anti-tumor mechanism of PD-1/PD-L1 blockade therapy is rejuvenating T cells, latest studies have demonstrated the complicated relationship between macrophages and PD-1/PD-L1 pathway during the progression and treatment of cancer and their engagement has serious implications for the therapeutic effect of PD-1/PD-L1 blockade agents. We focus on the dual regulation mechanisms between PD-1/PD-L1 axis and macrophages, and further clarify the mechanisms of resistance to PD-1/PD-L1 inhibitors related with macrophages.

CONCLUSION:

The combination of PD-1/PD-L1 blockade and macrophage-targeted therapy will exert synergetic anti-tumor effect and shape the future of cancer immunology and immunotherapy.

KEYWORDS:

Combination therapy; Macrophage; PD-1; PD-L1; T cell

PMID:
30963235
DOI:
10.1007/s00432-019-02879-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center